This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
Asthma: Revised Draft Report
A revised draft of the report Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks. This report incorporate feedback from public comment during a two week public comment period. A final report will be available in March 2016.View All Materials on this Topic or Go Back to View More Materials